The Role of Adjuvant Metronomic Chemotherapy in Increasing Overall Response Rate in Patients with Breast Cancer

Treatment paradigms against cancer have continuously evolved over the years. Having said that, with its prevalence of more than 2 million cases each year, breast cancer represents an urgent global priority [1]. Breast carcinomas accounted for 11.6 % of cancer cases and were the cause of mortality in as many as 6.6 % of women in the world in 2018 [2 ]. Toxicity and chemoresistance are significant hurdles in conventional chemotherapy and to avoid these issues, a new approach to drug administration, Metronomic Chemotherapy (MC) has emerged [3]. Metronomic chemotherapy involves treatment at regular, close intervals without prolonged breaks at doses considerably less than the Maximum-Tolerated Dose (MTD) [4]. Recently, MC is being used to intensify adjuvant chemotherapy as well as maintenance therapy for high-risk patients in the adjuvant settings [5